Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

被引:11
|
作者
Tsai, Yi-Giien [1 ,2 ,3 ,4 ]
Liao, Pei-Fen [3 ,5 ]
Hsiao, Kai-Hung [6 ]
Wu, Hung-Ming [7 ]
Lin, Ching-Yuang [8 ]
Yang, Kuender D. [9 ,10 ]
机构
[1] Changhua Christian Childrens Hosp, Dept Pediat, Changhua, Taiwan
[2] Kaohsiung Med Univ, Sch Med, Kaohsiung 807, Kaohsiung, Taiwan
[3] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[4] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taichung, Taiwan
[6] Changhua Christian Hosp, Dept Allergy Immunol & Rheumatol, Changhua, Taiwan
[7] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan
[8] China Med Univ Hosp, Childrens Hosp, Div Pediat Nephrol, Taichung, Taiwan
[9] MacKay Mem Hosp, Dept Pathol, New Taipei City, Taiwan
[10] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
systemic lupus erythematosus; lupus nephritis; regulatory T cells; interleukin-2; B regulatory cells; LOW-DOSE IL-2; B-CELLS; DISEASE-ACTIVITY; CD4(+); ACTIVATION; FOXP3; DIFFERENTIATION; SUPPRESSION; ASSOCIATION; CAPACITY;
D O I
10.3389/fimmu.2023.1230264
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] T helper cell subsets in the pathogenesis of systemic lupus erythematosus
    Reininger, L
    Santiago, ML
    Takahashi, S
    Fossati, L
    Izui, S
    ANNALES DE MEDECINE INTERNE, 1996, 147 (07): : 467 - 471
  • [2] Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus
    Taylor, Erin B.
    Sasser, Jennifer M.
    Maeda, Kenji J.
    Ryan, Michael J.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 317 (05) : F1274 - F1284
  • [3] Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus
    Humrich, Jens Y.
    Riemekasten, Gabriela
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (02) : 208 - 212
  • [4] Low-dose interleukin-2 therapy in systemic lupus erythematosus
    La Cava, Antonio
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2023, 4 (03): : 150 - 156
  • [5] Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus
    Hao, He
    Nakayamada, Shingo
    Ohkubo, Naoaki
    Yamagata, Kaoru
    Zhang, Mingzeng
    Shan, Yu
    Iwata, Shigeru
    Zhang, Tong
    Tanaka, Yoshiya
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [6] T Cells, Interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy
    Mak, Anselm
    CELLS, 2022, 11 (06)
  • [7] Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus erythematosus
    Rother, Nils
    van der Vlag, Johan
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [8] Interleukin-2 Deficiency Associated with Renal Impairment in Systemic Lupus Erythematosus
    Shao, Miao
    He, Jing
    Zhang, Ruijun
    Zhang, Xia
    Yang, Yue
    Li, Chun
    Liu, Xiaoyun
    Sun, Xiaolin
    Li, Zhanguo
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (02) : 117 - 124
  • [9] Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
    von Spee-Mayer, Caroline
    Siegert, Elise
    Abdirama, Dimas
    Rose, Angelika
    Klaus, Anika
    Alexander, Tobias
    Enghard, Philipp
    Sawitzki, Birgit
    Hiepe, Falk
    Radbruch, Andreas
    Burmester, Gerd-Ruediger
    Riemekasten, Gabriela
    Humrich, Jens Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1407 - 1415
  • [10] A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus
    Hanaoka, Hironari
    Nishimoto, Tetsuya
    Okazaki, Yuka
    Takeuchi, Tsutomu
    Kuwana, Masataka
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)